Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly profit beats estimates, helped by cost cuts

(Reuters) – Eli Lilly and Co (LLY.N) soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing, but revenue slipped as the stronger dollar hurt sales outside the United States. The U.S. drugmaker hopes to begin rebounding this year from three years of plunging sales and earnings caused by patent expirations on some […]

Read More »

Lilly Reports First-Quarter 2015 Results

INDIANAPOLIS, April 23, 2015 /PRNewswire/ — Revenue declined 1 percent due to the unfavorable impact of foreign exchange rates and the continuing impact of Cymbalta and Evista patent expirations, largely offset by the inclusion of revenue from Novartis Animal Health, higher U.S. prices, and increased volume for several products. First-quarter 2015 earnings per share were […]

Read More »

Abbvie’s CEO Gonzalez: We’re Now In Pharma’s ‘Top Tier’

Abbvie chief executive Rick Gonzalez, whose team beat out several more established drug giants in the successful bid for cancer pill maker Pharmacyclics, said today new and existing products will bring “top tier growth through the rest of the decade and beyond.” Gonzalez’ bold statement, setting the stage for a larger Abbvie, came during this […]

Read More »

Roche more confident in beating Alzheimer’s after Biogen data

(Reuters) – Swiss drugmaker Roche has “renewed confidence” that drugs targeting potentially brain-destroying plaque can fight Alzheimer’s disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O’Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer’s drugs, both of which suffered setbacks in 2014, in […]

Read More »

Teva-Mylan-Perrigo: Merger Mania In Pursuit Of Generic Margins

There are very few assurances in life, but in the field of generic pharmaceuticals, there are three certainties we are about to witness: 1. This is now the Spring of offers and counter-offers with the prices for generic drug makers setting new highs. Yesterday the Teva (TEVA) $82 per share offer for Mylan MYL -0.04% […]

Read More »

Novo launches Saxenda in US, sees more launches in 2015

(Reuters) – Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker. The company has said previously it expects sales from the drug to eventually reach $1 billion a year. It said in a statement […]

Read More »

Perrigo Rejects $30B Mylan Bid, Says Deal “Substantially Undervalues” Irish Firm

Pittsburgh, Penn.-based Mylan Inc. (MYL)’s $30 billion unsolicited bid for generic drugmaker Perrigo Company (PRGO) has been rejected by the company, after Perrigo said late Tuesday that the offer “substantially undervalues” Perrigo and “its future growth prospects and “is not in the best interests of Perrigo’s shareholders.” “Perrigo has a long history of driving above […]

Read More »

Biogen (BIIB) Loaded With Talented Women Execs, As CEO Pushes to Diversify Boardroom

Biogen has three women on its 10-member board of directors, an unusual feat in corporate America and the biotech industry. But instead of patting itself on the back with a round of attaboys and attagirls, the Cambridge powerhouse wanted to do more: help other companies put women on their boards. Where to find talented women? […]

Read More »

Amgen Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars

Thousand Oaks, Calif.-based Amgen (AMGN) announced stellar first quarter revenues yesterday, deflecting a failed asthma clinical trial. The company announced a total revenue increase of 11 percent for the first quarter of 2015 compared to the same period last year, rising from $4.521 billion to $5.033 billion. Revenues were driven by sales of Enrel, Prolia, […]

Read More »

Abbott reports first-quarter 2015 results

– FIRST-QUARTER DOUBLE-DIGIT OPERATIONAL SALES GROWTH– FIRST-QUARTER ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.47, ABOVE PREVIOUS GUIDANCE RANGE AND REFLECTING 38 PERCENT GROWTH; GAAP EPS FROM CONTINUING OPERATIONS OF $0.35– FULL-YEAR 2015 EPS GUIDANCE RANGE FOR CONTINUING OPERATIONS REMAINS UNCHANGED– COMPLETES THE SALE OF ITS DEVELOPED MARKETS BRANDED GENERICS PHARMACEUTICALS BUSINESS ABBOTT PARK, Ill., April […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom